JP2001523959A5 - - Google Patents

Download PDF

Info

Publication number
JP2001523959A5
JP2001523959A5 JP1998546254A JP54625498A JP2001523959A5 JP 2001523959 A5 JP2001523959 A5 JP 2001523959A5 JP 1998546254 A JP1998546254 A JP 1998546254A JP 54625498 A JP54625498 A JP 54625498A JP 2001523959 A5 JP2001523959 A5 JP 2001523959A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998546254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001523959A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/007968 external-priority patent/WO1998048009A2/en
Publication of JP2001523959A publication Critical patent/JP2001523959A/ja
Publication of JP2001523959A5 publication Critical patent/JP2001523959A5/ja
Ceased legal-status Critical Current

Links

JP54625498A 1997-04-21 1998-04-21 疾患のリボザイム処置のための物質および方法 Ceased JP2001523959A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4449297P 1997-04-21 1997-04-21
US60/044,492 1997-04-21
US4614797P 1997-05-09 1997-05-09
US60/046,147 1997-05-09
PCT/US1998/007968 WO1998048009A2 (en) 1997-04-21 1998-04-21 Materials and methods for ribozyme treatment of retinal diseases

Publications (2)

Publication Number Publication Date
JP2001523959A JP2001523959A (ja) 2001-11-27
JP2001523959A5 true JP2001523959A5 (enExample) 2005-12-02

Family

ID=26721633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54625498A Ceased JP2001523959A (ja) 1997-04-21 1998-04-21 疾患のリボザイム処置のための物質および方法

Country Status (8)

Country Link
US (1) US6225291B1 (enExample)
EP (1) EP0977841A2 (enExample)
JP (1) JP2001523959A (enExample)
AU (1) AU735788B2 (enExample)
BR (1) BR9808606A (enExample)
CA (1) CA2287508A1 (enExample)
NZ (1) NZ500427A (enExample)
WO (1) WO1998048009A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ500427A (en) 1997-04-21 2002-12-20 Univ Florida The use of ribozyme treatment for retinal diseases
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
JP2002542805A (ja) * 1999-04-30 2002-12-17 ユニバーシティ オブ フロリダ アデノ随伴ウイルス送達リボザイム組成物および使用方法
WO2000066720A2 (en) * 1999-04-30 2000-11-09 City Of Hope The use of adeno-associated virus (aav) deliver cytoprotective genes
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20030003582A1 (en) * 2001-05-08 2003-01-02 Tranzyme, Inc. Trans-viral vector mediated gene transfer to the retina
US20050222061A1 (en) 2002-04-18 2005-10-06 Schulte Ralf W Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
AU2003290586B2 (en) * 2002-11-04 2009-07-02 University Of Massachusetts Allele-specific RNA interference
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
EP2239328A3 (en) 2005-08-18 2011-01-05 Alnylam Pharmaceuticals Inc. Methods and compositions for treating neurological disease
US8257969B2 (en) * 2007-04-12 2012-09-04 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Genetic suppression and replacement
JP5832293B2 (ja) 2008-12-04 2015-12-16 オプコ ファーマシューティカルズ、エルエルシー 血管新生促進vegfイソ型を選択的に抑制する組成物および方法
US8450473B2 (en) 2009-04-30 2013-05-28 The Research Foundation Of State University Of New York Compositions and methods for therapy of macular degeneration
HUE041571T2 (hu) 2010-04-23 2019-05-28 Univ Florida RAAV-guanilát-cikláz-készítmények és ejárások 1-es típusú Leber-féle veleszületett vakság (LCA1) kezelésére
LT3137497T (lt) 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
PT4012035T (pt) 2014-09-16 2025-02-11 Genzyme Corp Vetores virais adenoassociados para tratar o glaucoma de miocilina (mioc)
EP4012035B1 (en) 2014-09-16 2024-11-06 Genzyme Corporation Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
MX391217B (es) 2015-02-26 2025-03-21 Ionis Pharmaceuticals Inc Moduladores de rodopsina p23h con especificidad de alelo.
US11653636B2 (en) * 2019-11-15 2023-05-23 University Of Ulsan Foundation For Industry Cooperation Method of making a rat model of retinal degeneration and rat model made thereby
WO2021155137A1 (en) 2020-01-29 2021-08-05 Genzyme Corporation Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037746A (en) 1986-12-03 1991-08-06 University Patents, Inc. RNA ribozyme polymerases, and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5646020A (en) 1992-05-14 1997-07-08 Ribozyme Pharmaceuticals, Inc. Hammerhead ribozymes for preferred targets
US5498539A (en) * 1992-07-02 1996-03-12 Daiichi Pharmaceutical Co., Ltd. Bovine endothelial nitric oxide synthase nucleic acids
US5639655A (en) 1993-01-19 1997-06-17 Ribozyme Pharmaceuticals, Inc. PML-RARA targeted ribozymes
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5646031A (en) 1995-05-16 1997-07-08 Northern Illinois University SArMV and sCYMVI hairpin ribozymes
GB9519299D0 (en) * 1995-09-21 1995-11-22 Farrar Gwyneth J Genetic strategy
GB9604449D0 (en) 1996-03-01 1996-05-01 Farrar Gwyneth J Genetic strategy ii
EP0977880A2 (en) 1997-04-21 2000-02-09 University Of Florida Materials and methods for treatment of retinal diseases
NZ500427A (en) 1997-04-21 2002-12-20 Univ Florida The use of ribozyme treatment for retinal diseases

Similar Documents

Publication Publication Date Title
JP2000509635A5 (enExample)
JP2000507042A5 (enExample)
JP2000509912A5 (enExample)
JP2000509637A5 (enExample)
JP2000509942A5 (enExample)
JP2001524836A5 (enExample)
JP2001523240A5 (enExample)
JP2000509587A5 (enExample)
JP2000507369A5 (enExample)
JP2000507433A5 (enExample)
JP2000508866A5 (enExample)
JP2000510793A5 (enExample)
JP2001508794A5 (enExample)
JP2000508841A5 (enExample)
JP2001514522A5 (enExample)
JP2000508680A5 (enExample)
JP2000509853A5 (enExample)
JP2000509755A5 (enExample)
JP2001524146A5 (enExample)
JP2000510969A5 (enExample)
JP2000510247A5 (enExample)
JP2000508102A5 (enExample)
JP2000508836A5 (enExample)
JP2000509520A5 (enExample)
JP2000509818A5 (enExample)